Inj daxibotulinumtoxina-lanm
Products billed under this code include Daxxify.
Payment limit per 1 UNIT, by effective quarter, 2Q25 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Daxxify.
Payment limit per 1 UNIT, by effective quarter, 2Q25 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Daxxify | Revance Therapeutics, Inc. | 72960-0112-01 | 100 | $325.20 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $3.252 | +$0.185 | 1 UNIT | Inj daxibotulinumtoxina-lanm | v1, posted September 17, 2026 |
| 3Q26 | $3.067 | −$0.026 | 1 UNIT | Inj daxibotulinumtoxina-lanm | v1, posted September 15, 2026 |
| 2Q26 | $3.093 | −$0.021 | 1 UNIT | Inj daxibotulinumtoxina-lanm | v1, posted September 15, 2026 |
| 1Q26 | $3.114 | −$0.034 | 1 UNIT | Inj daxibotulinumtoxina-lanm | v1, posted September 15, 2026 |
| 4Q25 | $3.148 | +$0.039 | 1 UNIT | Inj daxibotulinumtoxina-lanm | v1, posted September 8, 2026 |
| 3Q25 | $3.109 | +$0.117 | 1 UNIT | Inj daxibotulinumtoxina-lanm | v1, posted March 10, 2026 |
| 2Q25 | $2.992 | – | 1 UNIT | Inj daxibotulinumtoxina-lanm | v1, posted March 10, 2026 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.